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Background: We estimated the nationwide burden of nosocomial S. aureus bloodstream infection (SA-BSI), a major
cause of nosocomial infection, in South Korea.
Methods: To evaluate the nationwide incidence of nosocomial SA-BSI, cases of SA-BSI were prospectively collected
from 22 hospitals with over 500 beds over 4 months. Data on patient-days were obtained from a national health
insurance database containing the claims data for all healthcare facilities in South Korea. The additional cost of
SA-BSI was estimated through a matched case–control study. The economic burden was calculated from the sum
of the medical costs, the costs of caregiving and loss of productivity.
Results: Three hundred and thirty nine cases of nosocomial SA-BSI were included in the study: 254 cases of
methicillin-resistant SA-BSI (MRSA-BSI) and 85 cases of methicillin-susceptible SA-BSI (MSSA-BSI). Death related
to BSI occurred in 81 cases (31.9%) of MRSA-BSI and 12 cases (14.1%) of MSSA-BSI. The estimated incidence of
nosocomial MRSA-BSI was 0.12/1,000 patient-days and that of nosocomial MSSA-BSI, 0.04/1,000 patient-days. The
estimated annual cases of nosocomial BSI were 2,946 for MRSA and 986 for MSSA in South Korea. The additional
economic burden per case of nosocomial SA-BSI was US $20,494 for MRSA-BSI and $6,914 for MSSA-BSI. Total
additional annual cost of nosocomial SA-BSI was $67,192,559.
Conclusion: In view of the burden of nosocomial SA-BSI, a national strategy for reducing nosocomial SA-BSI is
urgently needed in South Korea.
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Healthcare-associated infections (HAIs) are a public
health challenge, greatly affecting patient safety. The
effects of HAIs include prolonged hospital stays, long-
term disabilities, and unnecessary deaths [1,2]. HAIs also
impose a significant economic burden on the healthcare
system. With increasing concern about patient safety in all* Correspondence: mdohmd@snu.ac.kr
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unless otherwise stated.circles of society, the prevention of HAIs has become an
important aspect of the patient safety agenda [3].
Accurate determination of the burden of HAIs is funda-
mental in formulating HAIs management policies. In the
United States, the estimated number of patients with at
least 1 or more HAIs was approximately 648,000 in 2011
[4]. In the U.S., the burden of HAIs is reported periodic-
ally [4-6], and changing trends can be used to indicate
infection control effectiveness. However, data on the
nationwide burden of HAI in Asian countries are lacking.
A national surveillance system, the Korean Nosocomial
Infection Surveillance System (KONIS) monitors HAIs [7],. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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included. Therefore, studies estimating the burden of na-
tionwide nosocomial infection are urgently required.
Staphylococcus aureus is one of the most important
and devastating pathogens among HAIs, and many studies
have shown that nosocomial S. aureus infection, especially
bloodstream infection (SA-BSI) causes a tremendous bur-
dens on the healthcare system [2,8-12]. Recently, we re-
ported the clinical characteristics and incidence of invasive
S. aureus infection in a population-based study [13]. In the
present study, we estimated the nationwide incidence and
additional cost of nosocomial SA-BSI in South Korea.
Methods
Study population and sources of data
The population for this study consisted of all patients ad-
mitted to South Korean hospitals with over 500 beds dur-
ing the June-September, 2011 study period. In 2011,
there were 317 tertiary and general hospitals in South
Korea, with 132,585 beds. Of these, 92 had over 500 beds,
with a total number of 72,025 beds. We included 22 of a
possible 92 hospitals, based on bed numbers and regional
distributions (Figure 1). We considered the population of
each region, and the proportion of selected hospitals in
each region reflected the national proportion of the regional
population. The 22 study hospitals had a total of 18,689
beds, which accounted for 25.9% of all hospitals with over
500 beds. All hospitals were acute-care hospitals.
We obtained patient-day data for the general population
and the study hospitals from the claims data of the HealthFigure 1 The locations of the 22 participating hospitals.Insurance Review and Assessment Service, a mandatory
medical insurance system that covers the entire population
of South Korea [14]. Because the study was performed in
2011 and the claims data for that year were not yet
complete, the data were extrapolated using the data for the
previous 5 years. Data on medical costs were obtained
from the administrative database of each study hospital.
Definitions
Nosocomial SA-BSI was defined as S. aureus infection
which occurred after 48 hours of hospitalization, and in
which S. aureus was isolated from blood culture. Cases of
SA-BSI occurring within 48 hours of hospitalization, but
for which the association between the BSI and the current
hospitalization was clear were taken to be nosocomial. Ex-
clusion criteria were as follows: 1) community-associated
infection, 2) healthcare-associated community-onset in-
fection, and 3) transfer to a study hospital after developing
SA-BSI in another hospital.
Mortality associated with SA-BSI was classified as 1)
definitely associated or 2) possibly associated. The former
was defined as described previously [15]: 1) positive
SA-BSI at the time of death or 2) death within 14 days
of the documentation of SA-BSI without any other
explanation. The latter was defined as: 1) death within
30 days of the documentation of SA-BSI without another
explanation. Catheter-associated infection was defined ac-
cording to the definition proposed by National Nosoco-
mial Infections Surveillance System [16]; in brief, positive
blood culture drawn from a central venous catheter used
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apparent source of the infection identified.
Hospital charges were defined as the amount hospitals
billed for healthcare services to patients. Hospital costs
were defined as the sum of hospital charges and the
amount that hospitals received from the Reimbursement
Service, a National Health Insurance Service in South
Korea. Costs were expressed in US dollars ($) at the ex-
change rate of 1100 Won per $ (as of 1st June, 2011).
Matched case–control study
We conducted a matched case–control study to estimate
the additional cost and length of hospitalization. In that
study, nosocomial SA-BSI cases meeting the following
conditions were excluded: 1) age under 18 years, 2) blood-
stream infection that developed more than 30 days after
admission. The latter criterion was adopted because of the
difficulty of selecting control patients who were free of
any nosocomial infections after 30 days of hospitalization.
The control patients were selected according to the fol-
lowing criteria: 1) age (±5 years compared to the matched
case), 2) date of admission (±2 weeks relative to the
matched case), 3) confinement in the same ward as the
case, and 4) underlying medical conditions similar to those
of the matched case, and free of nosocomial infections. If
two or more controls were identified, Charlson’s comor-
bidity index was used. Case–control pairs were classified
into survivor and non-survivor pairs, according to whether
the case patient was alive after 12 weeks of follow-up, irre-
spective of the outcome of the control patient.
Data variables
Baseline demographic variables, such as age, gender, and
underlying diseases were collected from the SA-BSI and
control patients. Data on variables related to clinical out-
comes, including length of hospitalization, mortality,
and intensive care unit use were also collected.
Data analyses
Estimation of annual incidence and number of SA-BSI
The annual number of SA-BSI cases was estimated in
two steps. In the first step, the annual incidence of SA-
BSI for the study hospitals was calculated as: (number of
all nosocomial SA-BSI cases during the 4 months) × 3/total
patient-days of the study hospitals for the year 2011.
In the second step, the annual number of SA-BSI cases
was estimated as: (annual incidence of SA-BSI for the
study hospitals) × (total patient-days of the 92 hospitals for
the year 2011).
Estimation of additional medical and societal costs of SA-BSI
We estimated the total additional costs of SA-BSI, includ-
ing direct medical and societal costs. Because the additional
medical cost and length of hospital stay could be influencedby survival, i.e., early deaths could lead to lower medical
costs and shorter hospital stays, the calculations were per-
formed separately for survivors and non-survivors.
The direct medical cost of SA-BSI was calculated as the
product of the additional medical cost due to SA-BSI and
the annual number of SA-BSI patients. The additional
medical cost was calculated by subtracting the median
hospital cost of the control patients from that of the corre-
sponding SA-BSI patients. The calculation was performed
separately for survivors and non-survivors.
The societal costs included the cost of caregiving, and
productivity losses due to extended hospitalization and
premature death. The cost of caregiving was calculated
as the product of the daily cost of the hired caregiver
and the excess length of stay (see above). Productivity
loss due to extended hospitalization was calculated as
the product of the daily wage of adults, the excess length
of hospitalization, and the labor participation rate, taken
as 25%. The productivity loss due to premature death
was calculated from the number of deaths associated with
SA-BSI and the annual wages reported by the Ministry of
Labor in Korea (Labor Statistics of Korea, Ministry of
Labor 2007; available from http://laborstat.molab.go.kr/).
The productivity loss due to the premature death of a
given patient was the sum of the annual wages up to the
time that patient would have reached 65 years of age if he
or she had not died. The annual discount rate was consid-
ered to be 5%. In calculating the latter, only patients under
65 years of age, the mandatory retirement age for almost
all professions, were included.
Data were analyzed with Microsoft Excel 2010 (Microsoft
Corp, Redmond, WA) and SPSS ver. 19.0 (SPSS Inc.,
Chicago, IL). The study was approved by the Institutional
Review Board of the National Evidence-based healthcare
Collaborating Agency and by each participating hospital.
The statistical data and analyses were reviewed by KY and
OSH.
Results
Baseline characteristics
During 4 months of the study period, 617 cases of SA-BSI
were reported, of which 368 (59.6%) were cases of MRSA-
BSI and 249 (40.4%) of MSSA-BSI. Community-associated
infections consisted of 43 cases of MRSA-BSI and 109
cases of MSSA-BSI; 71 of the MRSA-BSI and 55 of the
MSSA-BSI were healthcare-associated community-onset
infections. After excluding these cases, 254 cases of
MRSA-BSI and 85 cases of MSSA-BSI were included in
the analysis. The baseline characteristics of the patients
with nosocomial SA-BSI are shown in Table 1.
Clinical features of nosocomial SA-BSI
Of the 254 cases of MRSA-BSI, 104 (40.9%) occurred in the
ICU, compared with 18 (21.2%) of the 85 cases of MSSA-
Table 1 Baseline characteristics of the patients with Staphylococcus aureus bloodstream infections
Characteristic MRSA (n = 254) MSSA (n = 85) P-value
Gender (male/female) 167 (65.7%)/87 (34.3%) 41 (48.2%)/44 (51.8%) 0.004
Age, median (IQR) 66 (54–75) 58 (48–69)
Location at BSI onset
Ward 144 (56.7%) 60 (70.6%) 0.002
ER 6 (2.4%) 7 (8.2%)
ICU 104 (40.9%) 18 (21.2%)
Central line-associated bloodstream infection 94 (37.0%) 17 (20.0%) 0.004
Interval between admission and detection of BSI
1-7 days 53 (20.9%) 48 (56.5%)
8-14 days 56 (22.0%) 19 (22.4%)
15-21 days 35 (13.8%) 6 (7.1%)
22-30 days 19 (7.5%) 4 (4.7%)
31-60 days 56 (22.0%) 6 (7.1%)
61-90 days 14 (5.5%) 0
91-180 days 16 (6.3%) 1 (1.2%)
181-365 days 3 (1.2%) 1 (1.2%)
Over 365 days 2 (0.8%) 0
Abbreviations: MRSA Methicillin-resistant S. aureus, MSSA Methicillin-susceptible S. aureus, IQR Interquartile range, BSI Bloodstream infection, ER Emergency room,
ICU Intensive care unit.
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30 days of hospitalisation, only 77 cases (90.6%) of MSSA-
BSI occurred within this time period (Table 1).
Catheters were the most frequent primary site of infec-
tion for both MRSA-BSI and MSSA-BSI. Pneumonia and
surgical site infection were frequently related to MRSA-
BSI, while peripheral vein phlebitis and pneumonia were
frequently related to MSSA-BSI.
Deaths associated with BSI occurred in 81 cases (31.9%)
of MRSA-BSI. Of these, 64 were definitely associated with
BSI, and 17 were probably associated with BSI. For
MSSA-BSI, 12 deaths (14.1%) were definitely associated
with BSI. In a subgroup analysis of central-line associ-
ated bloodstream infections (CLABSI), 30 of 94 (31.9%)
MRSA-BSI patients died, and 27 out of the 30 deaths
were definitely associated with SA-BSI.
Of the 254 MRSA-BSI cases, 121 were excluded
from matching with control patients for the following
reasons: 91 developed BSI after more than 30 days of
hospitalization, 16 were under 18 years of age (two pa-
tients were both below 18 and developed BSI after more
than a month of hospitalization), and 16 could not be
matched with appropriate control patients. Of the 85
MSSA-BSI cases, 28 were excluded from the control pa-
tient matching: 8 patients developed BSI after more
than a month of hospitalization, 9 were under 18 (one
patient was both under 18 and developed BSI after more
than a month of hospitalization), and 12 patients couldnot be matched with appropriate controls. At the end of
this matching process, 56.0% of the cases were matched
with controls. Baseline characteristics, including gender,
age (excluding pediatric patients), proportions of CLABSI,
and mortality between included and excluded cases were
similar in the MRSA and MSSA-BSI groups. The clinical
and economic outcomes of the cases and controls shown
in Table 2 indicate that the median medical cost of
MRSA-BSI was $19,318, about 2.5 times that of controls
($7,092). For the patients with MSSA-BSI, the median
medical cost was $8,030 US dollars, almost double the
$4,475 US dollars for the control patients.
The estimated annual incidence of nosocomial SA-BSI
The estimated annual incidence of nosocomial SA-BSI per
1,000 patient-days is shown in Table 3. The estimated an-
nual incidence of MRSA-BSI was 0.12/1,000 patient-days,
and that of MSSA-BSI was 0.04/1,000 patient-days. The
estimated annual number of nosocomial SA-BSI cases was
2,946 for MRSA and 986 for MSSA. The estimated annual
number of deaths was 943 for MRSA-BSI and 139 for
MSSA-BSI.
The estimated additional cost of nosocomial SA-BSI
MRSA
The total estimated additional cost of SA-BSI is shown
in Table 4. The additional medical cost for one case of
MRSA-BSI was $11,259 in the survivor group and $14,772
Table 2 Clinical and economic characteristics of case and control patients with S. aureus bloodstream infections
(a) MRSA vs. control
Characteristic MRSA (n = 133) Control (n = 133) P-value
Male gender 86 (64.7%) 84 (63.2%) 0.798
Age (years), median (IQR) 67 (56–76.5) 68 (56–75)
Died 49 (36.8%) 18 (13.5%) <0.001
Duration of hospitalization (days), mean (SD) 38.5 (26.8) 25.8 (28.0) <0.001
Survivor pairs 44.5 (29.6) 25.2 (29.0) <0.001
Non-survivor pairs 28.0 (16.5) 27.1 (26.2) 0.843
Charlson’s comorbidity index (SD) 4.92 (2.4) 4.5 (2.0) 0.094
Hospital cost ($), median (IQR) 19,318 (9,852-29,438) 7,092 (2,864-14,609)
Survivor pairs 18,699 (9,660-28,369) 7,440 (3,095-14,907)
Non-survivor pairs 19,647 (10,812-29,821) 4,875 (2,551-11,850)
Hospital charge ($), median (IQR) 4,661 (2,240-7,959) 2,359 (870–4,128)
Survivor pairs 4,423 (2,093-8,015) 2,394 (1,077-4,384)
Non-survivor pairs 4,763 (2,596-7,930) 1,841 (626–3,706)
(b) MSSA vs. control
Characteristic MSSA (n = 57) Control (n = 57) P-value
Male gender 26 (45.6%) 31 (54.4%) 0.349
Age (years), median (IQR) 63 (51.5-71.5) 61 (50.5-72.0)
Died 11 (19.3%) 4 (7.0%) 0.052
Duration of hospitalization (days), mean (SD) 29.4 (20.7) 18.1 (24.4) 0.010
Survivor pairs 31.5 (21.7) 15.5 (12.9) < 0.001
Non-survivor pairs 17.9 (8.7) 32.8 (56.1) 0.139
Charlson’s comorbidity index (SD) 4.8 (2.4) 4.1 (2.1) 0.108
Hospital cost ($), median (IQR) 8,030 (4,998-17,733) 4,475 (2,714-9,973)
Survivor pairs 9,247 (4,991-19,564) 4,449 (2,692-10,090)
Non-survivor pairs 6,255 (3,952-9,815) 5,847 (2,151-10,771)
Hospital charge ($), median (IQR) 2,054 (918–4,753) 1,517 (669–3,673)
Survivor pairs 2,056 (845–4,822) 1,442 (619–3,309)
Non-survivor pairs 1,713 (1,229-3,041) 1,855 (723–4,364)
Abbreviations: MRSA Methicillin-resistant S. aureus, IQR Interquartile range, SD Standard deviation.
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the excess days of hospitalization were $927 and $273 in
the survivor and non-survivor groups, respectively. The
total additional cost of MRSA-BSI was estimated to be
$60,375,506 annually, corresponding to $20,494 per case
of MRSA-BSI. Medical costs accounted for 60.4% of the
total additional costs, and productivity loss due to prema-
ture death for 35.4%.
MSSA
The additional medical cost of MSSA-BSI was $4,797 in
the survivor group and $408 in the non-survivor group.
The cost of caregiving due to excess hospitalization was
$818 in the survivor group. However, in the non-survivor
group, the length of hospital stay was shorter in theSA-BSI group than in the control, and no additional
cost was generated. The total additional cost of MSSA-BSI
was estimated to be $6,817,053 annually, which corre-
sponds to $6,914 per case of MSSA-BSI. Medical costs
accounted for 60.4% of the total additional costs, and
productivity loss due to premature death for 27.7%.
Discussion
We set out to determine the annual national financial
burden of SA-BSI in South Korea. We estimated that the
annual incidence of nosocomial SA-BSI was 0.16/1000
patient-days, and that there were 3,932 cases of nosoco-
mial SA-BSI, resulting in 1,082 fatalities in 2011. We
also estimated that the additional medical cost of noso-
comial BSI was $12,226 per case of MRSA-BSI and
Table 3 Incidence of nosocomial Staphylococcus aureus bloodstream infection and estimated annual number of cases nationwide
Age group Actual number Total patient-days for
22 hospitals
Incidence of SA BSI (per 1,000
patient-days)
Total patient-days for 92
hospitals
Estimated annual number
of SA-BSI cases
Male Female Total Male Female Total Male Female Total Male Female Total Male Female Total
Total MRSA 167 87 254 3,273,055 2,987,471 6,260,525 0.15 0.09 0.12 12,865,024 11,342,270 24,207,293 1969 991 2946
MSSA 41 44 85 0.04 0.04 0.04 483 501 986
0-9 MRSA 6 7 13 389,736 292,724 682,460 0.05 0.07 0.06 1,272,094 960,391 2,232,485 59 69 128
MSSA 3 5 8 0.02 0.05 0.04 29 49 79
10-19 MRSA 4 0 4 157,139 97,236 254,375 0.08 0.00 0.05 543,108 333,271 876,379 41 0 41
MSSA 0 1 1 0.00 0.03 0.01 0 10 10
20-29 MRSA 2 1 3 156,072 160,269 316,341 0.04 0.02 0.03 568,594 591,027 1,159,621 22 11 33
MSSA 0 2 2 0.00 0.04 0.02 0 22 22
30-39 MRSA 8 4 12 208,994 291,053 500,048 0.11 0.04 0.07 804,148 1,062,531 1,866,679 92 44 134
MSSA 3 0 3 0.04 0.00 0.02 35 0 34
40-49 MRSA 9 8 17 375,999 383,098 759,097 0.07 0.06 0.07 1,501,241 1,464,574 2,965,815 108 92 199
MSSA 4 4 8 0.03 0.03 0.03 48 46 94
50-59 MRSA 38 10 48 599,353 478,517 1,077,870 0.19 0.06 0.13 2,392,430 1,898,890 4,291,320 455 119 573
MSSA 13 9 22 0.07 0.06 0.06 156 107 263
60-69 MRSA 48 11 59 660,593 515,558 1,176,151 0.22 0.06 0.15 2,774,688 2,005,009 4,779,697 605 128 719
MSSA 13 9 22 0.06 0.05 0.06 164 105 268
70-79 MRSA 34 29 63 568,375 554,828 1,123,203 0.18 0.16 0.17 2,311,691 2,156,892 4,468,583 415 338 752
MSSA 4 11 15 0.02 0.06 0.04 49 128 179
>80 MRSA 18 17 35 156,794 214,188 370,981 0.34 0.24 0.28 697,029 869,686 1,566,715 240 207 443
MSSA 1 3 4 0.02 0.04 0.03 13 37 51
Abbreviations: MRSA Methicillin-resistant S. aureus, MSSA Methicillin-susceptible S. aureus, SA-BSI S. aureus bloodstream infection.
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Table 4 Estimate of the annual economic burden of nosocomial S. aureus bloodstream infection in South Korea
MRSA MSSA
Additional cost
per patient ($)
Annual number
of patients
Additional
annual cost ($)
Additional cost
per patient ($)
Annual number
of patients
Additional
annual cost ($)
Medical cost, median
Survivors 11,259 2003 22,551,777 4,797 847 4,063,059
Non survivors 14,772 943 13,929,996 408 139 56,712
Sub-total 2946 36,481,773 986 4,119,771
Cost of care giving 986
Survivors 927 2003 1,857,327 818 847 693,000
Non survivors 273 943 257,182 0* 139
Subtotal 2946 2,114,509 986 693,000
Productivity loss due to extended hospitalization
Survivors Male 187 1368 255,546 165 425 70,051
Female 126 635 80,163 111 421 46,895
Non survivors Male 55 601 33,020 0* 59
Female 37 342 12,698 0* 80
Subtotal 2946 381,428 986 116,946
Productivity loss due to premature death 943 21,397,796 139 1,887,336
Total additional cost of nosocomial SA-BSI 2946 60,375,506 986 6,817,053
Abbreviations: MRSA Methicillin-resistant S. aureus, MSSA Methicillin-susceptible S. aureus, SA-BSI S. aureus bloodstream infection.
*Because hospital stays were shorter in the non-survivors in the MSSA group, no additional cost was generated.
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burden of nosocomial SA-BSI in South Korea was esti-
mated to be > $67.2 million, of which medical costs com-
prised 60.4%. This is the first nationwide nosocomial
surveillance data on the clinical and financial burdens from
an Asian country.
In a previous study, we reported that the estimated
number of invasive S. aureus infection was 21,000 cases
in 3 areas of South Korea, and that 55% of them were
nosocomial infections [13]. This suggested that the in-
cidence of S. aureus bacteremia was 43.3 per 100,000
person-years. A recent study from a single Korean hospital
reported that the incidence of MRSA-BSI was 0.12/1,000
patient-days [17], which is in line with the results of the
present study. The Korea Centers for Disease Control and
Prevention (K-CDC) collect data on multidrug-resistant
organisms via a laboratory-based surveillance system, and
4,153 cases of MRSA-BSI were reported to the K-CDC in
2012 [18], a figure in line with our findings. Unfortunately,
KONIS, another surveillance system, collects data on
nosocomial infections in intensive care units only, and
excluding those at general wards, thus our data are
not comparable with those of KONIS [7]. Notably, a
Taiwanese study also found that the incidence of SA-BSI
was 0.01-0.88/1,000 patient-days [19].
We included only S. aureus in this study, and therefore
we could not estimate the incidence of nosocomial BSI
of other organisms. S. aureus usually accounts for 10-20%of all causes of nosocomial BSI [20-22], and a recent study
from South Korea also reported similar results [23]. If
we assumed S. aureus comprised 10-20% of nosocomial
BSI, the annual number of nosocomial BSI of all organ-
isms could be estimated as range from 19,660 to 39,320
in 2011 in South Korea. As the total number of hospital
admissions was 6,453,839 in 2011 [24], approximately
30.5-60.9 per 10,000 admitted patients are estimated to
suffer from nosocomial BSI. It is of interest that the esti-
mated burden of BSI is very close to that reported from
England, which ranged from 19,202 to 28,804 patients
per year [25].
Our matched-control study showed that the additional
medical costs were $12,226 and $3,555, for MRSA-BSI
and MSSA-BSI, respectively. These are comparable to
data from Canada, with additional costs for MRSA-BSI
of $6,878 to $17,553 [12,26]. However, these costs are
small compared to the additional costs in the U.S.A of
$23,690 to $27,083 for MRSA-BSI and $9,661 to $19,212
for MSSA [8-10]. This vast difference in the additional
hospital costs is mainly due to differences between the
healthcare systems, especially in terms of the medical
price-setting, insurance system and reimbursement
policy.
Nosocomial SA-BSI imposes a large economic burden
on our healthcare system. We found that the additional
cost of nosocomial SA-BSI was > $67.2 million. This is an
enormous burden, but because the proportion SA-BSI
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is unknown, we could not estimate the total burden of
nosocomial infection. Considering that this study did
not include BSI of other organisms and other HAIs such
as pneumonia, urinary tract infections and wound infec-
tions, HAIs can be understood to impose a huge economic
burden on our healthcare system. Studies of the nationwide
economic burden of HAIs have been reported for many
countries [11,27]. De Kraker et al. estimated that the
increasing burden imposed by antimicrobial-resistant
organisms will surpass that of other major diseases. In
the U.S.A., the total cost of the 5 major HAIs was $9.8
billion and initiatives are considered essential to reduce
HAIs [28]. Our data provide an important foundation for
creating a nationwide plan to reduce HAIs.
This study had certain limitations. First, the sam-
pling period was short. We accept that a short sam-
pling period may distort the estimates made, because
of seasonal variations in disease incidence, and sam-
pling bias. However, seasonal variations in S. aureus
HAIs are less common than are variations in skin and
soft tissue infections, community-acquired infections,
and in pediatric populations [29,30]. Many studies have
found that nosocomial infection rates do not vary sea-
sonally [31,32]. We earlier also found that no seasonal
variability was evident [13]. In surveillance of K-CDC,
monthly variation in incidence of MRSA bacteremia
was also not evident [18].
Secondly, because we studied only hospitals with
over 500 beds, data on the nosocomial SA-BSI inci-
dence in smaller hospitals were not included. We
selected hospitals that employed infectious disease
specialists, because each SAB case was required to be
reviewed by such a specialist. In South Korea, more
than 90% of infectious diseases specialists work in
university-affiliated hospitals or large hospitals (over
500 beds), and we thus could not include medium-
sized and small hospitals in our study. As it is not
known whether the incidence of HAIs in small or
medium-sized hospitals is higher or lower than that in
large hospitals, our data cannot be extrapolated to
hospitals with less than 500 beds. According to data
provided by the multidrug-resistant organism surveil-
lance system in South Korea, cases of MRSA-BSI in
hospitals with 300–499 beds account for 11.7% of all
cases. Therefore, considering the extent of nosocomial
SA-BSI in hospitals with 500 beds or less, we estimate
that more than 10-20% of all SA-BSI cases were omitted
in our estimations, and, hence, the calculated cost may be
at the lower end of the real nationwide figure.
Conclusion
In conclusion, approximately 3,932 cases of nosocomial
SA-BSI occurred in 2011 in the South Korean hospitalssurveyed (those with 500 or more beds), and 1,082 pa-
tients died. The economic burden of nosocomial SA-BSI
exceeded $67.2 million. A national strategy to reduce such
infections featuring a campaign to improve hand hygiene
practice, dissemination of bundle approach when man-
aging central catheter, and periodic estimation of the bur-
den of such infections, is urgently needed.
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